AAPL   318.90 (+0.00%)
MSFT   182.48 (-0.56%)
FB   234.08 (-0.35%)
GOOGL   1,428.22 (+1.06%)
AMZN   2,426.26 (-0.44%)
NVDA   351.18 (-2.73%)
CGC   20.15 (+3.76%)
BABA   202.78 (+1.54%)
MU   46.42 (+3.29%)
GE   6.85 (+6.70%)
AMD   54.12 (-1.90%)
T   31.02 (+3.82%)
GILD   73.68 (+0.46%)
DIS   121.86 (+3.25%)
NFLX   415.39 (-3.24%)
BAC   24.48 (+8.03%)
BA   144.98 (+5.42%)
AAPL   318.90 (+0.00%)
MSFT   182.48 (-0.56%)
FB   234.08 (-0.35%)
GOOGL   1,428.22 (+1.06%)
AMZN   2,426.26 (-0.44%)
NVDA   351.18 (-2.73%)
CGC   20.15 (+3.76%)
BABA   202.78 (+1.54%)
MU   46.42 (+3.29%)
GE   6.85 (+6.70%)
AMD   54.12 (-1.90%)
T   31.02 (+3.82%)
GILD   73.68 (+0.46%)
DIS   121.86 (+3.25%)
NFLX   415.39 (-3.24%)
BAC   24.48 (+8.03%)
BA   144.98 (+5.42%)
AAPL   318.90 (+0.00%)
MSFT   182.48 (-0.56%)
FB   234.08 (-0.35%)
GOOGL   1,428.22 (+1.06%)
AMZN   2,426.26 (-0.44%)
NVDA   351.18 (-2.73%)
CGC   20.15 (+3.76%)
BABA   202.78 (+1.54%)
MU   46.42 (+3.29%)
GE   6.85 (+6.70%)
AMD   54.12 (-1.90%)
T   31.02 (+3.82%)
GILD   73.68 (+0.46%)
DIS   121.86 (+3.25%)
NFLX   415.39 (-3.24%)
BAC   24.48 (+8.03%)
BA   144.98 (+5.42%)
AAPL   318.90 (+0.00%)
MSFT   182.48 (-0.56%)
FB   234.08 (-0.35%)
GOOGL   1,428.22 (+1.06%)
AMZN   2,426.26 (-0.44%)
NVDA   351.18 (-2.73%)
CGC   20.15 (+3.76%)
BABA   202.78 (+1.54%)
MU   46.42 (+3.29%)
GE   6.85 (+6.70%)
AMD   54.12 (-1.90%)
T   31.02 (+3.82%)
GILD   73.68 (+0.46%)
DIS   121.86 (+3.25%)
NFLX   415.39 (-3.24%)
BAC   24.48 (+8.03%)
BA   144.98 (+5.42%)
Log in

OTCMKTS:ELOXEloxx Pharmaceuticals Stock Price, Forecast & News

$3.66
+0.16 (+4.57 %)
(As of 05/26/2020 02:43 PM ET)
Add
Compare
Today's Range
$3.51
Now: $3.66
$3.77
50-Day Range
$1.56
MA: $2.55
$3.50
52-Week Range
$1.44
Now: $3.66
$13.37
Volume100,218 shs
Average Volume152,339 shs
Market Capitalization$146.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Read More
Eloxx Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ELOX
CUSIPN/A
CIKN/A
Phone858-909-0749

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$146.87 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) Frequently Asked Questions

How has Eloxx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eloxx Pharmaceuticals' stock was trading at $2.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ELOX stock has increased by 27.1% and is now trading at $3.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eloxx Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eloxx Pharmaceuticals.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals (OTCMKTS:ELOX) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.09. View Eloxx Pharmaceuticals' earnings history.

What price target have analysts set for ELOX?

6 equities research analysts have issued 1 year target prices for Eloxx Pharmaceuticals' stock. Their forecasts range from $3.00 to $11.00. On average, they anticipate Eloxx Pharmaceuticals' share price to reach $7.67 in the next year. This suggests a possible upside of 109.5% from the stock's current price. View analysts' price targets for Eloxx Pharmaceuticals.

Has Eloxx Pharmaceuticals been receiving favorable news coverage?

Headlines about ELOX stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eloxx Pharmaceuticals earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutEloxx Pharmaceuticals.

Who are some of Eloxx Pharmaceuticals' key competitors?

What other stocks do shareholders of Eloxx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eloxx Pharmaceuticals investors own include BioXcel Therapeutics (BTAI), Novavax (NVAX), Opko Health (OPK), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Ardelyx (ARDX), Aurinia Pharmaceuticals (AUPH), Axsome Therapeutics (AXSM) and Boeing (BA).

Who are Eloxx Pharmaceuticals' key executives?

Eloxx Pharmaceuticals' management team includes the following people:
  • Mr. Robert E. Ward, Chairman & CEO (Age 60)
  • Dr. Silvia Noiman, Founder & Director (Age 62)
  • Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)
  • Dr. Pedro Huertas, Chief Medical Officer (Age 63)
  • Dr. Colin Scott M.B., Ch.B., Medical Director (Age 66)

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELOX."

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.53%), Altshuler Shaham Ltd (2.84%), Geode Capital Management LLC (0.96%), DAFNA Capital Management LLC (0.48%), Nuveen Asset Management LLC (0.29%) and Morgan Stanley (0.19%). View institutional ownership trends for Eloxx Pharmaceuticals.

Which major investors are selling Eloxx Pharmaceuticals stock?

ELOX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., UBS Group AG, DAFNA Capital Management LLC, Squarepoint Ops LLC, and Wells Fargo & Company MN. View insider buying and selling activity for Eloxx Pharmaceuticals.

Which major investors are buying Eloxx Pharmaceuticals stock?

ELOX stock was purchased by a variety of institutional investors in the last quarter, including Altshuler Shaham Ltd, Geode Capital Management LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Eloxx Pharmaceuticals.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $3.66.

How big of a company is Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals has a market capitalization of $146.87 million.

What is Eloxx Pharmaceuticals' official website?

The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at 858-909-0749 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.